Oncotelic Therapeutics, Inc. (OTLC)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Oncotelic Therapeutics, Inc. (OTLC) with AI Score 38/100 (Weak). Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for orphan oncology indications. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Oncotelic Therapeutics, Inc. (OTLC) Healthcare & Pipeline Overview
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in orphan oncology treatments, with its lead drug OT-101 targeting TGF-ß2 in advanced clinical trials for pancreatic cancer and glioblastoma, positioning it within a competitive biotechnology landscape focused on novel cancer therapies.
Investment Thesis
Oncotelic Therapeutics, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The primary value driver is the successful completion of Phase 3 clinical trials for OT-101 in pancreatic cancer and glioblastoma. Positive trial outcomes could lead to regulatory approval and subsequent commercialization, potentially generating significant revenue. The company's focus on orphan oncology indications offers the possibility of accelerated regulatory pathways and market exclusivity. However, the company's OTC listing, limited financial resources, and dependence on the success of a single drug candidate represent significant risks. Investors should carefully consider the binary nature of clinical trial outcomes and the challenges of navigating the regulatory landscape.
Based on FMP financials and quantitative analysis
Key Highlights
- OT-101 is in Phase 3 clinical trials for pancreatic cancer and glioblastoma, representing a critical milestone.
- Focus on orphan oncology indications offers potential for accelerated regulatory pathways.
- Developing OT-101 for potential treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
- Market Cap of $0.02B reflects the early-stage nature and associated risks of the company.
- P/E ratio of -9.32 indicates the company is not currently profitable.
Competitors & Peers
Strengths
- Focus on orphan oncology indications.
- Lead product candidate in Phase 3 clinical trials.
- Proprietary technology platform.
- Potential for orphan drug designation and market exclusivity.
Weaknesses
- Limited financial resources.
- Dependence on the success of a single drug candidate.
- OTC listing.
- Small team size.
Catalysts
- Upcoming: Data readout from Phase 3 clinical trials for OT-101 in pancreatic cancer and glioblastoma (late 2026 or early 2027).
- Upcoming: Potential partnerships and collaborations with larger pharmaceutical companies (2026 or 2027).
- Upcoming: Potential for orphan drug designation to be granted for specific indications (2026 or 2027).
- Ongoing: Clinical development of OXi4503 for AML and MDS, with potential for Phase 2 trials in 2026.
- Ongoing: Exploration of OT-101 in treating various viral infections, with potential for clinical trials in 2027.
Risks
- Potential: Clinical trial failures for OT-101 or other drug candidates.
- Potential: Regulatory hurdles and delays in obtaining drug approvals.
- Ongoing: Competition from larger pharmaceutical companies with greater resources.
- Ongoing: Difficulty securing funding to support research and development activities.
- Ongoing: Risks associated with OTC listing, including limited liquidity and transparency.
Growth Opportunities
- Successful Completion of OT-101 Phase 3 Trials: The successful completion of Phase 3 clinical trials for OT-101 in pancreatic cancer and glioblastoma represents a significant growth opportunity. Positive results could lead to regulatory approval and commercialization, potentially generating substantial revenue. The market for pancreatic cancer therapeutics is projected to reach $3.8 billion by 2028, while the glioblastoma market is expected to reach $2.1 billion by 2027. Timeline: Anticipated data readout in late 2026 or early 2027.
- Expansion of OT-101 into Viral Indications: Oncotelic is exploring the potential of OT-101 in treating various viral infections, including severe acute respiratory syndrome and coronavirus. This represents a significant growth opportunity, given the ongoing need for effective antiviral therapies. The global market for antiviral drugs is projected to reach $70 billion by 2025. Timeline: Preclinical and early-stage clinical development ongoing, with potential for clinical trials in 2027.
- Development of OXi4503 for AML and MDS: The development of OXi4503 for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) represents another growth opportunity. The market for AML therapeutics is projected to reach $3.5 billion by 2028, while the MDS market is expected to reach $2.2 billion by 2027. Timeline: Clinical development ongoing, with potential for Phase 2 trials in 2026.
- Partnerships and Collaborations: Oncotelic could pursue partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. These partnerships could provide access to funding, expertise, and distribution networks. Timeline: Ongoing, with potential for partnerships to be announced in 2026 or 2027.
- Orphan Drug Designation and Market Exclusivity: Oncotelic's focus on orphan oncology indications offers the potential for orphan drug designation, which provides market exclusivity and other regulatory benefits. This can protect the company's products from competition and enhance their commercial value. Timeline: Ongoing, with potential for orphan drug designation to be granted for specific indications in 2026 or 2027.
Opportunities
- Successful completion of Phase 3 clinical trials.
- Expansion into viral indications.
- Partnerships and collaborations.
- Accelerated regulatory pathways for orphan drugs.
Threats
- Clinical trial failures.
- Regulatory hurdles.
- Competition from larger pharmaceutical companies.
- Difficulty securing funding.
Competitive Advantages
- Intellectual property protection for its drug candidates.
- Orphan drug designation and market exclusivity.
- Proprietary technology platform for developing targeted therapies.
About OTLC
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for the treatment of orphan oncology indications. The company's primary focus is on developing drugs that address unmet medical needs in rare cancers. Their lead product candidate, OT-101, an antisense oligonucleotide targeting TGF-ß2, is currently undergoing Phase 3 clinical trials for the treatment of pancreatic cancer and glioblastoma. OT-101 is also being explored for its potential in treating various viral infections, including severe acute respiratory syndrome and coronavirus. In addition to OT-101, Oncotelic is developing OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes, and CA4P for advanced metastatic melanoma. The company's research and development efforts are centered in Agoura Hills, California. Oncotelic aims to improve the lives of patients with rare and difficult-to-treat cancers through targeted therapies that address the underlying mechanisms of disease. The company operates with a lean structure, managing its clinical trials and drug development programs with a team of 26 employees.
What They Do
- Develop drugs for orphan oncology indications.
- Focus on therapies for rare and difficult-to-treat cancers.
- Lead product candidate OT-101 targets TGF-ß2.
- Conduct Phase 3 clinical trials for pancreatic cancer and glioblastoma.
- Develop OT-101 for treatment of various viruses.
- Develop OXi4503 for treatment of acute myeloid leukemia and myelodysplastic syndromes.
- Develop CA4P for treatment of advanced metastatic melanoma.
Business Model
- Develop and commercialize novel therapies for orphan oncology indications.
- Generate revenue through the sale of approved drugs.
- Potentially generate revenue through partnerships and collaborations with larger pharmaceutical companies.
Industry Context
Oncotelic Therapeutics, Inc. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The company focuses on the orphan oncology market, a segment that often benefits from regulatory incentives and market exclusivity. The broader biotechnology industry is experiencing growth driven by advancements in genomics, personalized medicine, and immunotherapy. However, companies like Oncotelic face challenges in securing funding, navigating clinical trials, and competing with larger, more established pharmaceutical companies such as ACHFF (Amgen) and BLOZF (Bayer).
Key Customers
- Patients with rare and difficult-to-treat cancers.
- Healthcare providers who treat patients with these cancers.
- Hospitals and cancer centers.
Financials
Chart & Info
Oncotelic Therapeutics, Inc. (OTLC) stock price: Price data unavailable
Latest News
-
Sapu Nano to Launch Deciparticle™ Platform and Present Clinical Pipeline at BIO-Europe Spring 2026
globenewswire.com · Mar 24, 2026
-
Sapu Nano to Present Everolimus Toxicology Data at SOT 2026 Annual Meeting
globenewswire.com · Mar 23, 2026
-
Financial Analysis: Oncotelic Therapeutics (OTCMKTS:OTLC) versus Lexicon Pharmaceuticals (NASDAQ:LXRX)
defenseworld.net · Mar 15, 2026
-
NetworkNews Audio Announces Audio Press Release (APR) Discussing Growing Investor Attention on Companies Holding Clinical-Stage Portfolios
globenewswire.com · Feb 23, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OTLC.
Price Targets
Wall Street price target analysis for OTLC.
MoonshotScore
What does this score mean?
The MoonshotScore rates OTLC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Sapu Nano to Launch Deciparticle™ Platform and Present Clinical Pipeline at BIO-Europe Spring 2026
Sapu Nano to Present Everolimus Toxicology Data at SOT 2026 Annual Meeting
Financial Analysis: Oncotelic Therapeutics (OTCMKTS:OTLC) versus Lexicon Pharmaceuticals (NASDAQ:LXRX)
NetworkNews Audio Announces Audio Press Release (APR) Discussing Growing Investor Attention on Companies Holding Clinical-Stage Portfolios
Leadership: Vuong Trieu
CEO
Vuong Trieu serves as the CEO of Oncotelic Therapeutics, Inc. His background includes extensive experience in managing and leading biotechnology companies. He is responsible for overseeing the company's strategic direction, clinical development programs, and financial operations. His leadership is crucial for navigating the complex regulatory landscape and securing funding for the company's research and development efforts.
Track Record: Under Vuong Trieu's leadership, Oncotelic has advanced its lead product candidate, OT-101, into Phase 3 clinical trials. He has also overseen the expansion of the company's pipeline to include additional drug candidates targeting various oncology indications. His strategic decisions have been instrumental in securing partnerships and collaborations to support the company's growth.
OTLC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Oncotelic Therapeutics, Inc. may not meet the minimum financial or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited regulatory oversight and may not be required to file regular financial reports with the SEC. This lack of transparency can increase the risk for investors compared to companies listed on major exchanges like the NYSE or NASDAQ, which have stricter listing standards and reporting requirements.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and regulatory approvals.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any legal or regulatory actions against the company.
- OT-101 is in Phase 3 clinical trials.
- Focus on orphan oncology indications.
- Company has a CEO and management team.
- Headquartered in the US.
OTLC Healthcare Stock FAQ
What does Oncotelic Therapeutics, Inc. do?
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for orphan oncology indications. Their lead product candidate, OT-101, is an antisense oligonucleotide targeting TGF-ß2, currently in Phase 3 clinical trials for pancreatic cancer and glioblastoma. The company also develops other drug candidates, including OXi4503 for acute myeloid leukemia and myelodysplastic syndromes, and CA4P for advanced metastatic melanoma. Oncotelic aims to address unmet medical needs in rare cancers through targeted therapies.
What do analysts say about OTLC stock?
As of 2026-03-17, there is no readily available analyst coverage for Oncotelic Therapeutics, Inc. (OTLC) due to its OTC listing and small market capitalization. Investors should conduct their own thorough research and consider the inherent risks associated with investing in OTC stocks. Key valuation metrics are difficult to assess given the company's current lack of profitability and limited financial disclosure. Growth considerations revolve around the successful completion of clinical trials and potential regulatory approvals.
What are the main risks for OTLC?
The main risks for Oncotelic Therapeutics, Inc. include the potential for clinical trial failures, regulatory hurdles, competition from larger pharmaceutical companies, and difficulty securing funding. The company's dependence on the success of OT-101 represents a significant risk, as a failure in Phase 3 trials could have a material adverse effect on the company's prospects. Additionally, the company's OTC listing exposes investors to risks associated with limited liquidity, transparency, and regulatory oversight.
What are the key factors to evaluate for OTLC?
Oncotelic Therapeutics, Inc. (OTLC) currently holds an AI score of 38/100, indicating low score. Key strength: Focus on orphan oncology indications.. Primary risk to monitor: Potential: Clinical trial failures for OT-101 or other drug candidates.. This is not financial advice.
How frequently does OTLC data refresh on this page?
OTLC prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven OTLC's recent stock price performance?
Recent price movement in Oncotelic Therapeutics, Inc. (OTLC) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on orphan oncology indications.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider OTLC overvalued or undervalued right now?
Determining whether Oncotelic Therapeutics, Inc. (OTLC) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying OTLC?
Before investing in Oncotelic Therapeutics, Inc. (OTLC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- OTC market data may be limited or unreliable.
- AI analysis pending for OTLC.